Literature DB >> 32634599

Neural closed-loop deep brain stimulation for freezing of gait.

Matthew N Petrucci1, Raumin S Neuville1, M Furqan Afzal1, Anca Velisar1, Chioma M Anidi1, Ross W Anderson1, Jordan E Parker1, Johanna J O'Day2, Kevin B Wilkins1, Helen M Bronte-Stewart3.   

Abstract

Entities:  

Year:  2020        PMID: 32634599      PMCID: PMC8189032          DOI: 10.1016/j.brs.2020.06.018

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


× No keyword cloud information.
Dear Editor, Freezing of gait (FOG) is a devastating symptom of Parkinson’s disease (PD), affecting over half of the patient population [1] and negatively impacting mobility and patient quality of life. This symptom has been difficult to treat with dopaminergic medication, is associated with arrhythmic gait, and can become refractory over time [2]. Moreover, it is debated to what extent deep brain stimulation (DBS) provided in an open-loop manner (olDBS) can mitigate FOG [3]. Neural closed-loop deep brain stimulation (clDBS) has been demonstrated to alleviate the signs and symptoms of PD by adjusting stimulation in response to elevations in local field potential (LFP) beta band (13–30 Hz) power in the subthalamic nucleus (STN). Improvements in tremor and bradykinesia on clDBS have been observed using beta power as the control variable in both single and dual threshold algorithms [4-6]. We have shown that STN olDBS attenuated pathological beta fluctuations while improving FOG [7]. To date, no study has used similar closed-loop paradigms to reduce FOG. In this paper, we demonstrate preliminary evidence that clDBS driven by STN beta band power was superior to conventional olDBS in reducing the percent time freezing and arrhythmicity during a stepping in place (SIP) task. One male participant (age: 63.2 years, off UPDRS-III: 55, disease duration: 5.1 years, akinetic-rigid subtype) with PD and FOG participated in the study. The participant was implanted with an investigative sensing neurostimulator (Medtronic Activa® PC + S, FDA IDE approved) and bilateral STN DBS leads (Medtronic model 3389). All procedures were approved by the Stanford University Institutional Review Board and the participant provided informed written consent. The participant performed the SIP task [8] during four stimulation conditions in the following order: off DBS (OFF), on closed-loop DBS (clDBS), on his clinical open-loop contacts and parameters used for therapy (olDBSClinical), on open-loop DBS that matched the contacts and average parameters used in the clDBS condition (olDBSMatched) (see Table S1 and Fig. 1 for the stimulation parameters). Both olDBS conditions were included to directly compare clDBS to the participant’s clinical open-loop settings and a matched olDBS condition. All testing was performed in the off-medication state (refrained for 12 hours for short- and 24/48 hours for long-acting dopaminergic medication). The clDBS was modulated by the power of local field potentials contained in the beta frequency range [4]. The maximum voltage that provided clinical improvement without side effects (VMax) in each STN was determined (left STN: 4.3 V, right STN: 4.5 V). The dual threshold control algorithm parameters were determined from beta band power during movement. This “movement band” beta power was measured during voltage titration SIP trials at 5 voltages between 0 and 100% of VMax presented in random order (Figure S1). The “movement band” was set to ±3 Hz around the peak frequency of elevated beta band power during SIP (15 Hz for both STNs) [7]. The upper and lower values of the dual threshold controller were set to the average beta power measured during the stepping in place task at the minimum voltage (VMin) that showed improvement in stepping and freezing behavior (upper beta threshold) and at VMax (lower beta threshold); VMin was 25% of VMax. Previously established ramp rates were used for both STNs [9] (0.1 V/0.4 s up, and 0.1 V/0.8 s down).
Fig. 1.

Stepping in place vertical ground reaction forces for the participant (A) off stimulation, (B) on clinical open-loop stimulation, (C) on matched open-loop stimulation, and (D) on neural closed-loop stimulation. FOG events detected by automated algorithm [8] are indicated by the vertical green lines. Percent time freezing and arrhythmicity of the whole trial or up to the first freeze are presented above each condition. The volume of tissue activated from each STN is to the right of each condition in red with the stimulation parameters below. Although stimulation improved stepping in all conditions, closed-loop stimulation showed the lowest arrhythmicity and % time freezing. Arrhythmicity (E) of the first 25 seconds and up to the first freeze or whole trial (if there were no freezing events) are plotted for each condition. Arrhythmicity was overall higher off stimulation and continued to worsen later in the trial for all conditions except for closed-loop stimulation.

An automated algorithm detected freezing events when the participant’s feet did not lift off the force plates [8]. FOG and freezing behavior were assessed using the percent time freezing and arrhythmicity (coefficient of variation (CV) of stride time), respectively. Total electrical energy delivered (TEED) and volume of tissue activated (VTA) was calculated for all stimulation conditions (see supplemental methods). In the OFF-DBS condition the subject exhibited FOG at the start of the stepping task, was able to step for ~20 seconds and then experienced prolonged FOG as his repetitive stepping behavior deteriorated (i.e., loss of force modulation, Fig. 1A). While on olDBSClinical and olDBSMatched, there was improvement in the duration of normal stepping but FOG episodes were still detected (Fig. 1B and C). During clDBS, only a short start hesitation was detected at the beginning of the episode (Fig. 1D). The percent time freezing was 68.7% OFF DBS, 2.3% during olDBSClinical, 23.5% during olDBSMatched, and 1.5% during clDBS. SIP arrhythmicity was lower in all stimulation conditions compared to OFF (54.9% OFF, 18.2% olDBSClinical, 27.4% olDBSMatched, 5.2% clDBS, Fig. 1A–D). There was an increase in arrhythmicity after the first 25 seconds of the trial during both olDBSClinical and olDBSMatched, but during clDBS, stepping remained rhythmic (Fig. 1E). There was no difference in TEED between olDBSMatched and clDBS, and the average TEED was 2% higher in clDBS vs. olDBSClinical (Table S2). These findings, to the best of our knowledge, are the first to demonstrate that neural closed-loop DBS (clDBS), using a dual threshold algorithm based on beta power determined by therapeutic voltage titrations, was superior to clinical open-loop DBS (olDBSClinical), matched open-loop DBS (olDBSMatched), and no DBS (OFF) in reducing FOG in PD. Freezing behavior, manifesting as arrhythmic stepping and lack of maintaining a consistent rate of force/amplitude control during stepping (i.e., the “sequence effect” [10]), also improved more during clDBS compared to olDBSClinical, olDBSMatched, and OFF. Both olDBSClinical and olDBSMatched resulted in a similar deterioration of stepping behavior despite a small increase in TEED and VTA during olDBSMatched. However, stepping behavior was maintained during clDBS even though the TEED and VTA were nearly identical to olDBSMatched. These findings suggest that allowing the stimulation to adapt during the trial may allow the motor system to sustain or regain movement control, whereas continuous stimulation (with a similar or same amount of TEED and VTA) cannot prevent the “sequence effect” that contributes to arrhythmic gait and FOG [10] because it is not changing in response to fluctuating STN activity. Overall, these findings warrant further investigation into the use of clDBS for improving FOG as well as other Parkinsonian symptoms. Future investigations should evaluate how much the stimulation needs to adapt to maintain a therapeutic effect while also minimizing the energy requirement.
  9 in total

1.  Gait freezing in Parkinson's disease and the stride length sequence effect interaction.

Authors:  Rachel Chee; Anna Murphy; Mary Danoudis; Nellie Georgiou-Karistianis; Robert Iansek
Journal:  Brain       Date:  2009-05-11       Impact factor: 13.501

2.  Repetitive stepping in place identifies and measures freezing episodes in subjects with Parkinson's disease.

Authors:  Julie Nantel; Camille de Solages; Helen Bronte-Stewart
Journal:  Gait Posture       Date:  2011-06-29       Impact factor: 2.840

3.  Dual threshold neural closed loop deep brain stimulation in Parkinson disease patients.

Authors:  A Velisar; J Syrkin-Nikolau; Z Blumenfeld; M H Trager; M F Afzal; V Prabhakar; H Bronte-Stewart
Journal:  Brain Stimul       Date:  2019-02-25       Impact factor: 8.955

4.  Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's disease.

Authors:  Chioma Anidi; Johanna J O'Day; Ross W Anderson; Muhammad Furqan Afzal; Judy Syrkin-Nikolau; Anca Velisar; Helen M Bronte-Stewart
Journal:  Neurobiol Dis       Date:  2018-09-06       Impact factor: 5.996

5.  Predictors of freezing in Parkinson's disease: a survey of 6,620 patients.

Authors:  Michael Macht; Yvonne Kaussner; Jens Carsten Möller; Karin Stiasny-Kolster; Karla Maria Eggert; Hans-Peter Krüger; Heiner Ellgring
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

Review 6.  Medical treatment of freezing of gait.

Authors:  Nir Giladi
Journal:  Mov Disord       Date:  2008       Impact factor: 10.338

Review 7.  Deep brain stimulation effect on freezing of gait.

Authors:  Murielle U Ferraye; Bettina Debû; Pierre Pollak
Journal:  Mov Disord       Date:  2008       Impact factor: 10.338

8.  Adaptive deep brain stimulation in advanced Parkinson disease.

Authors:  Simon Little; Alex Pogosyan; Spencer Neal; Baltazar Zavala; Ludvic Zrinzo; Marwan Hariz; Thomas Foltynie; Patricia Limousin; Keyoumars Ashkan; James FitzGerald; Alexander L Green; Tipu Z Aziz; Peter Brown
Journal:  Ann Neurol       Date:  2013-07-12       Impact factor: 10.422

9.  Eight-hours adaptive deep brain stimulation in patients with Parkinson disease.

Authors:  Mattia Arlotti; Sara Marceglia; Guglielmo Foffani; Jens Volkmann; Andres M Lozano; Elena Moro; Filippo Cogiamanian; Marco Prenassi; Tommaso Bocci; Francesca Cortese; Paolo Rampini; Sergio Barbieri; Alberto Priori
Journal:  Neurology       Date:  2018-02-14       Impact factor: 9.910

  9 in total
  11 in total

1.  Electrocorticography is superior to subthalamic local field potentials for movement decoding in Parkinson's disease.

Authors:  Robert Mark Richardson; Wolf-Julian Neumann; Timon Merk; Victoria Peterson; Witold J Lipski; Benjamin Blankertz; Robert S Turner; Ningfei Li; Andreas Horn
Journal:  Elife       Date:  2022-05-27       Impact factor: 8.713

2.  Modulation of Beta Oscillations in the Pallidum During Externally Cued Gait.

Authors:  Chiahao Lu; Sommer L Amundsen-Huffmaster; Kenneth H Louie; Matthew N Petrucci; Tara Palnitkar; Remi Patriat; Noam Harel; Michael C Park; Jerrold L Vitek; Colum D MacKinnon; Scott E Cooper
Journal:  Front Signal Process (Lausanne)       Date:  2022-05-20

3.  Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data.

Authors:  Muhammad Nazmuddin; Ingrid H C H M Philippens; Teus van Laar
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

4.  Perspective: Evolution of Control Variables and Policies for Closed-Loop Deep Brain Stimulation for Parkinson's Disease Using Bidirectional Deep-Brain-Computer Interfaces.

Authors:  Helen M Bronte-Stewart; Matthew N Petrucci; Johanna J O'Day; Muhammad Furqan Afzal; Jordan E Parker; Yasmine M Kehnemouyi; Kevin B Wilkins; Gerrit C Orthlieb; Shannon L Hoffman
Journal:  Front Hum Neurosci       Date:  2020-08-31       Impact factor: 3.169

5.  Closed-Loop Deep Brain Stimulation to Treat Medication-Refractory Freezing of Gait in Parkinson's Disease.

Authors:  Rene Molina; Chris J Hass; Stephanie Cernera; Kristen Sowalsky; Abigail C Schmitt; Jaimie A Roper; Daniel Martinez-Ramirez; Enrico Opri; Christopher W Hess; Robert S Eisinger; Kelly D Foote; Aysegul Gunduz; Michael S Okun
Journal:  Front Hum Neurosci       Date:  2021-03-01       Impact factor: 3.169

6.  Proceedings of the Eighth Annual Deep Brain Stimulation Think Tank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies.

Authors:  Vinata Vedam-Mai; Karl Deisseroth; James Giordano; Gabriel Lazaro-Munoz; Winston Chiong; Nanthia Suthana; Jean-Philippe Langevin; Jay Gill; Wayne Goodman; Nicole R Provenza; Casey H Halpern; Rajat S Shivacharan; Tricia N Cunningham; Sameer A Sheth; Nader Pouratian; Katherine W Scangos; Helen S Mayberg; Andreas Horn; Kara A Johnson; Christopher R Butson; Ro'ee Gilron; Coralie de Hemptinne; Robert Wilt; Maria Yaroshinsky; Simon Little; Philip Starr; Greg Worrell; Prasad Shirvalkar; Edward Chang; Jens Volkmann; Muthuraman Muthuraman; Sergiu Groppa; Andrea A Kühn; Luming Li; Matthew Johnson; Kevin J Otto; Robert Raike; Steve Goetz; Chengyuan Wu; Peter Silburn; Binith Cheeran; Yagna J Pathak; Mahsa Malekmohammadi; Aysegul Gunduz; Joshua K Wong; Stephanie Cernera; Wei Hu; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Wissam Deeb; Addie Patterson; Kelly D Foote; Michael S Okun
Journal:  Front Hum Neurosci       Date:  2021-04-19       Impact factor: 3.169

7.  Differential Effects of Pathological Beta Burst Dynamics Between Parkinson's Disease Phenotypes Across Different Movements.

Authors:  Raumin S Neuville; Matthew N Petrucci; Kevin B Wilkins; Ross W Anderson; Shannon L Hoffman; Jordan E Parker; Anca Velisar; Helen M Bronte-Stewart
Journal:  Front Neurosci       Date:  2021-11-11       Impact factor: 5.152

8.  Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury.

Authors:  Joshua K Wong; Günther Deuschl; Robin Wolke; Hagai Bergman; Muthuraman Muthuraman; Sergiu Groppa; Sameer A Sheth; Helen M Bronte-Stewart; Kevin B Wilkins; Matthew N Petrucci; Emilia Lambert; Yasmine Kehnemouyi; Philip A Starr; Simon Little; Juan Anso; Ro'ee Gilron; Lawrence Poree; Giridhar P Kalamangalam; Gregory A Worrell; Kai J Miller; Nicholas D Schiff; Christopher R Butson; Jaimie M Henderson; Jack W Judy; Adolfo Ramirez-Zamora; Kelly D Foote; Peter A Silburn; Luming Li; Genko Oyama; Hikaru Kamo; Satoko Sekimoto; Nobutaka Hattori; James J Giordano; Diane DiEuliis; John R Shook; Darin D Doughtery; Alik S Widge; Helen S Mayberg; Jungho Cha; Kisueng Choi; Stephen Heisig; Mosadolu Obatusin; Enrico Opri; Scott B Kaufman; Prasad Shirvalkar; Christopher J Rozell; Sankaraleengam Alagapan; Robert S Raike; Hemant Bokil; David Green; Michael S Okun
Journal:  Front Hum Neurosci       Date:  2022-03-04       Impact factor: 3.473

Review 9.  Stepping up to meet the challenge of freezing of gait in Parkinson's disease.

Authors:  Simon Lewis; Stewart Factor; Nir Giladi; Alice Nieuwboer; John Nutt; Mark Hallett
Journal:  Transl Neurodegener       Date:  2022-05-01       Impact factor: 9.883

10.  Cortical phase-amplitude coupling is key to the occurrence and treatment of freezing of gait.

Authors:  Zixiao Yin; Guanyu Zhu; Yuye Liu; Baotian Zhao; Defeng Liu; Yutong Bai; Quan Zhang; Lin Shi; Tao Feng; Anchao Yang; Huanguang Liu; Fangang Meng; Wolf Julian Neumann; Andrea A Kühn; Yin Jiang; Jianguo Zhang
Journal:  Brain       Date:  2022-07-29       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.